Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 1/20 | 0.62 |
| ▸ | P2RY14 | Q15391 | 5/20 | 0.59 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.54 |
| ▸ | P2RY6 | Q15077 | 10/20 | 0.54 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.53 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.53 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.53 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.53 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL918582 | 1.00 | TYMP (0.62) | TYMPP2RY14P2RY2P2RY6SLC28A1 | |
| SCHEMBL1317089 | 1.00 | TYMP (0.62) | TYMPP2RY14P2RY2P2RY6SLC28A1 | |
| SCHEMBL12513082 | 1.00 | TYMP (0.62) | TYMPP2RY14P2RY2P2RY6SLC28A1 | |
| SCHEMBL26502752 | 1.00 | TYMP (0.62) | TYMPP2RY14P2RY2P2RY6SLC28A1 | |
| SCHEMBL12434636 | 1.00 | TYMP (0.62) | TYMPP2RY14P2RY2P2RY6SLC28A1 | |
| SCHEMBL26502736 | 0.93 | TYMP (0.56) | TYMPP2RY14P2RY2P2RY6SLC28A1 | |
| SCHEMBL4085510 | 0.92 | SLC28A1 (0.62) | TYMPP2RY14P2RY2P2RY6SLC28A1 | |
| SCHEMBL8332109 | 0.92 | SLC28A1 (0.62) | TYMPP2RY14P2RY2P2RY6SLC28A1 | |
| SCHEMBL22983983 | 0.92 | TYMP (0.53) | TYMPP2RY14P2RY2P2RY6SLC28A1 | |
| SCHEMBL8209464 | 0.92 | P2RY6 (0.54) | TYMPP2RY14P2RY2P2RY6SLC28A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025038971-A1 | OLIGONUCLEOTIDES CONTAINING A LIGAND AT A NUCLEOBASE, 2' POSITION, OR 3' POSITION | ADARX PHARMACEUTICALS, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| US-10457945-B2 | UNA oligomers for therapeutics with prolonged stability | ARCTURUS THERAPEUTICS, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20180237780-A1 | UNA OLIGOMERS FOR THERAPEUTICS WITH PROLONGED STABILITY | MARINA BIOTECH, INC. | 2018-08-23 | — | — | US | disclosed |
| US-9944929-B2 | UNA single stranded oligomers for therapeutics | ARCTURUS THERAPEUTICS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| EP-1995253-B1 | METHOD FOR DETACHING PROTECTING GROUP ON NUCLEIC ACID | NIPPON SHINYAKU CO LTD (JP) | 2016-12-21 | — | — | EP | disclosed |
| EP-3045535-A1 | HYDROXYMETHYL SUBSTITUTED RNA OLIGONUCLEOTIDES AND RNA COMPLEXES | Arcturus Therapeutics, Inc. (US) | 2016-07-20 | — | — | EP | disclosed |
| US-20160168567-A1 | UNA SINGLE STRANDED OLIGOMERS FOR THERAPEUTICS | MARINA BIOTECH, INC. | 2016-06-16 | — | — | US | disclosed |
| CN-101679978-B | Hydroxymethyl substituted RNA oligonucleotides and RNA complexes | ARCTURUS THERAPEUTICS, INC. (US) | 2016-05-04 | — | — | CN | disclosed |
| EP-2162538-B1 | OLIGOMERS FOR THERAPEUTICS | ARCTURUS THERAPEUTICS INC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-9303260-B2 | UNA duplex oligomers for therapeutics | ARCTURUS THERAPEUTICS, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| EP-1644479-A4 | FUNCTIONAL SYNTHETIC MOLECULES AND MACROMOLECULES FOR GENE DELIVERY | GRINSTAFF MARK W (US) | 2008-04-23 | — | — | EP | disclosed |
| EP-1639121-A4 | SYNTHESIS OF BETA -L-2-DEOXY NUCLEOSIDES | IDENIX CAYMAN LTD (KY) | 2008-04-16 | — | — | EP | disclosed |
| US-20070282097-A1 | Phosphoramidite Compound And Method For Producing Oligo-Rna | NIPPON SHINYAKU CO., LTD. (JP) | 2007-12-06 | — | — | US | disclosed |
| EP-1795536-A1 | PHOSPHORAMIDITE COMPOUND AND METHOD FOR PRODUCING OLIGO-RNA | Nippon Shinyaku Co., Ltd. (JP) | 2007-06-13 | — | — | EP | disclosed |
| US-20060241071-A1 | Functional synthetic molecules and macromolecules for gene delivery | FIFTH BASE LLC | 2006-10-26 | — | — | US | disclosed |
| EP-1644479-A2 | FUNCTIONAL SYNTHETIC MOLECULES AND MACROMOLECULES FOR GENE DELIVERY | Grinstaff, Mark, W. (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1639121-A2 | SYNTHESIS OF BETA -L-2-DEOXY NUCLEOSIDES | Idenix (Cayman) Limited (KY) | 2006-03-29 | — | — | EP | disclosed |
| US-20050059632-A1 | Synthesis of beta-L-2'-deoxy nucleosides | NOVARTIS AG (CH) | 2005-03-17 | — | — | US | disclosed |
| WO-2005007810-A2 | FUNCTIONAL SYNTHETIC MOLECULES AND MACROMOLECULES FOR GENE DELIVERY | GRINSTAFF MARK W (US) | 2005-01-27 | — | — | WO | disclosed |
| WO-2005003374-A2 | SYNTHESIS OF β-L-2-DEOXY NUCLEOSIDES | IDENIX (CAYMAN) LIMITED (KY) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241071-A1 | Functional synthetic molecules and macromolecules for gene delivery | ANXA6, STING1, POLRMT | TYMP 2413/4885P2RY14 3315/4885P2RY2 3058/4885 |
| US-10457945-B2 | UNA oligomers for therapeutics with prolonged stability | NOP2, NONO, NSUN3 | TYMP 482/4885P2RY14 3103/4885P2RY2 1939/4885 |
| US-20070282097-A1 | Phosphoramidite Compound And Method For Producing Oligo-Rna | NSUN2, NSUN3, XRN2 | TYMP 485/4885P2RY14 1889/4885P2RY2 1095/4885 |
| US-20180237780-A1 | UNA OLIGOMERS FOR THERAPEUTICS WITH PROLONGED STABILITY | NOP2, NONO, NSUN3 | TYMP 482/4885P2RY14 3103/4885P2RY2 1939/4885 |
| US-20050059632-A1 | Synthesis of beta-L-2'-deoxy nucleosides | DUT, DERA, RNASEL | TYMP 25/4885P2RY14 1903/4885P2RY2 1816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.